IBBQ News and Press, Invesco Nasdaq Biotechnology ETF From 11/11/21

We are particularly enthused about a broad area that falls within the life science tools and services category, where we find many companies that are enabling innovative breakthroughs. Other growth themes in healthcare have either arisen or accelerated due to the COVID-19 pandemic. Th...

In making the case for less stringent regulations, pharmaceutical companies highlight the distinctions between list prices and net prices. The industry projects potential negative implications for patient access and R&D investments, and support in Congress has historically be limi...

The after-effects of pandemic-era policies will be with us for some time - with many supply chains and labor markets still experiencing significant disruption. Everyone likes to complain about drug prices, but here is the unpleasant truth: discovering new drugs is expensive and risky....

Taking a look at how the expected Q3 ’21 sector revenue growth rates have changed since mid-August ’21 or the unofficial end of Q2 ’21 earnings season. Per Bespoke’s research, the S&P 500 has now reached “extremely oversold” levels, worse ...

We’ve seen economic data in recent months moderate after record growth in the first half of 2021. In financials, the rise of many fintech companies and the growth of digital payments has really disrupted the traditional banking industry, creating new options for consumers. ...

Defensive stocks are often misunderstood. In recent years, even when they have delivered strong and steady earnings, returns have disappointed. After a period of underperformance for defensives, a broadening market can represent real opportunity. Beyond utilities, we believe that ...

In any market’s upswing, there are always going to be people who make the case that “it’s different this time”, and historically, most of the time, that argument doesn’t hold up. I have never seen so many interesting and novel therapeutic opportuniti...